Genelux (GNLX) Stock Price, News & Analysis

Company Overview

GeneLux Therapeutics, Inc. (NASDAQ: GNLX) is a clinical-stage biotechnology company focused on developing targeted immunotherapies using its proprietary oncolytic virus platform. The company’s lead candidate, GL-ONC1 (Olvi-Vec), is an engineered vaccinia virus designed to selectively infect and destroy cancer cells while stimulating systemic anti-tumor immune responses. Through a combination of preclinical research and ongoing clinical trials, GeneLux aims to advance its platform across a range of solid tumors and hematologic malignancies, with an emphasis on improving patient outcomes in difficult-to-treat cancers.

Originally founded as Genelux Corporation and rebranded in 2022 to GeneLux Therapeutics, the company has established a diversified pipeline that includes monotherapy and combination studies in ovarian cancer, malignant pleural mesothelioma and urothelial carcinoma. GeneLux has built internal manufacturing capabilities compliant with Good Manufacturing Practice (GMP) standards to support scale-up for late-stage clinical trials. Strategic collaborations with academic research centers and contract development organizations bolster the company’s translational research and regulatory filing efforts.

Headquartered in New York with research and process development laboratories in Oklahoma City, GeneLux maintains a global footprint through investigator-initiated clinical studies in Europe and Asia. By partnering with leading oncology centers, the company seeks to generate robust clinical data and explore novel combination strategies involving immune checkpoint inhibitors and other emerging therapies. This geographic and strategic diversity reflects GeneLux’s commitment to addressing unmet medical needs across multiple regions and patient populations.

Led by President and Chief Executive Officer Jeffrey Shore, who brings extensive experience in virology and immuno-oncology, GeneLux’s management team combines deep expertise in drug development, regulatory affairs and commercial strategy. The board of directors and scientific advisory board include seasoned professionals with backgrounds in clinical operations, translational research and corporate governance. Together, they guide GeneLux’s mission to innovate in oncolytic virus therapy and advance new treatment options for patients battling refractory cancers.

Key Stats

• Today's Range: $3.20 to $3.41
• 50-Day Range: $2.31 to $3.48
• 52-Week Range: $1.60 to $5.89
• Volume: 122,526 shs
• Average Volume: 193,594 shs
• Market Capitalization: $127.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.75
• Consensus Rating: Buy

Genelux Stock Analysis - MarketRank™

Genelux scored higher than 25% of companies evaluated by MarketBeat, and ranked 834th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Genelux has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Genelux has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Genelux are expected to decrease in the coming year, from ($0.88) to ($1.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Genelux is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genelux is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Genelux has a P/B Ratio of 4.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.10% of the float of Genelux has been sold short.

Short Interest Ratio / Days to Cover

Genelux has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.

Change versus previous month

Short interest in Genelux has recently increased by 11.48%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genelux does not currently pay a dividend.

Dividend Growth

Genelux does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.10% of the float of Genelux has been sold short.

Short Interest Ratio / Days to Cover

Genelux has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.

Change versus previous month

Short interest in Genelux has recently increased by 11.48%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.97

News Sentiment

Genelux has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Genelux this week, compared to 1 article on an average week.

Search Interest

Only 4 people have searched for GNLX on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

4 people have added Genelux to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genelux insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.30% of the stock of Genelux is held by insiders.

Percentage Held by Institutions

Only 37.33% of the stock of Genelux is held by institutions.

GNLX Stock Analysis - Frequently Asked Questions

How have GNLX shares performed this year?

Genelux's stock was trading at $2.36 on January 1st, 2025. Since then, GNLX shares have increased by 43.0% and is now trading at $3.3750.

How were Genelux's earnings last quarter?

Genelux Corporation (NASDAQ:GNLX) announced its earnings results on Thursday, May, 8th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.03.

When did Genelux IPO?

Genelux (GNLX) raised $16 million in an initial public offering on Thursday, January 26th 2023. The company issued 2,500,000 shares at $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets acted as the underwriters for the IPO.

How do I buy shares of Genelux?

Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Genelux own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genelux investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/14/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GNLX
• CIK: 1231457
• Web: www.genelux.com
• Phone: 805-267-9889
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Genelux: $17.75
• High Price Target: $30.00
• Low Price Target: $8.00
• Potential Upside/Downside: +425.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$29.87 million
• Net Margins: N/A
• Pretax Margin: -373,362.47%
• Return on Equity: -93.04%
• Return on Assets: -74.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.67
• Quick Ratio: 4.67

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.76 per share
• Price / Book: 4.45

Miscellaneous

• Outstanding Shares: 37,735,000
• Free Float: 34,226,000
• Market Cap: $127.54 million
• Optionable: Not Optionable
• Beta: -0.34